IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS (IPF) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS (IPF) trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new daily pill slow lung scarring in IPF?
Disease control Not yet recruitingThis phase 2 trial tests whether an experimental drug called HSK50042 can improve lung function in adults with idiopathic pulmonary fibrosis (IPF), a chronic condition that causes lung scarring and breathing difficulties. Participants take HSK50042 or a placebo once daily for 26 …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a new drug slow lung scarring in IPF?
Disease control Not yet recruitingThis phase 3 trial is testing whether an experimental drug called AK3280 can slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a condition that causes progressive lung scarring. About 263 adults aged 40 and older with IPF will receive either A…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE3 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Smart cap aims to boost medication adherence in lung disease patients
Disease control Not yet recruitingThis study will test if a smart pill bottle cap, called FORTISKAP™, helps people with serious lung diseases like pulmonary fibrosis, sarcoidosis, and pulmonary hypertension take their oral medications more consistently. About 100 participants will either use the smart cap or rece…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Cosmos Rx, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New IPF drug candidate enters first human safety trial
Disease control Not yet recruitingThis early-stage trial tests a new tablet called HW241045 in 102 healthy volunteers to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a lung-scarring disease. The study is randomized, double-blind, and placebo-contr…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to slow lung scarring in IPF patients
Disease control Not yet recruitingThis phase 2 trial tests whether adding dextromethorphan to the standard drug nidanib helps people with idiopathic pulmonary fibrosis (IPF). About 60 adults aged 40 and older will take either the combo or nidanib alone for 12 weeks. The main goal is to see if lung function (FVC) …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could inhaled stem cell therapy help stiff lungs?
Disease control Not yet recruitingThis early study tests whether inhaling tiny particles from stem cells (extracellular vesicles) is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Nine adults with mild-to-moderate IPF will inhale the treatment tw…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Huan Ye • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Stem cells injected for lung scarring: early trial begins
Disease control Not yet recruitingThis early-phase trial will test a stem cell product called REGEND007 in 12 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The stem cells are given through an IV, and the main goal is to check safety and find the right do…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: EARLY_PHASE1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental cell therapy targets lung scarring in End-Stage disease
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy for people with end-stage idiopathic pulmonary fibrosis (IPF), a disease that causes severe lung scarring and breathing failure. The therapy uses specially engineered immune cells to target and reduce scarring in the lungs. The stud…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Talking therapy via video aims to boost self-care in lung disease patients
Knowledge-focused Not yet recruitingThis study tests whether motivational interviewing, delivered through video calls and online platforms, can improve self-care in 124 adults with idiopathic pulmonary fibrosis (IPF). Participants will be randomly assigned to receive the counseling or usual care. Researchers will m…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:18 UTC
-
Massive study aims to decode lung disease progression
Knowledge-focused Not yet recruitingThis study will observe 2,864 people with idiopathic pulmonary fibrosis (IPF) to learn how the disease changes over time and how it relates to traditional Chinese medicine syndromes. Researchers will track lung function, exercise ability, quality of life, and other health markers…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
1,000-Patient study to see if ancient herbal medicine slows lung scarring
Knowledge-focused Not yet recruitingThis study will follow 1,000 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and breathing problems. Researchers will compare those who take traditional Chinese medicine (TCM) for at least three months a year to those who do not. The g…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:18 UTC